Avantium Pharma BV, has been spun out from Avantium Holding BV in a management buy-out to create Crystallics.
The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies, as well as, pharmaceutical contract manufacturing organizations and agrochemical companies.
Gunnar Staaf, Chief Executive Officer, commented: “Crystallics’ core business focus will be in solid state research and pre-formulation, an area where we have built up considerable expertise over the last decade. I believe our proprietary technology, experienced team, together with a strong customer focus, make Crystallics an ideal partner.”
Solid state research plays a central role in the pharmaceutical industry. Active pharmaceutical ingredients can exist in a number of solid forms, such as polymorphs, salts, co-crystals, hydrates, or amorphous forms.
Various solid state forms of the same active pharmaceutical ingredient will have different characteristics that can have a significant impact on the safety and efficacy of a drug product.
Marcel Hoffmann, Chief Scientific Officer, said: “We believe in a tailored, science based approach to meet the customer’s project objectives and budgets. Quality and speed will be at the heart of our research approach.”